Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Elpamotide + VEGFR1-1084 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Elpamotide | VEGFR2-169 | Elpamotide (VEGFR2-169) is a KDR (VEGFR2) HLA-A*2402 allele specific peptide vaccine, which may stimulate cytotoxic T cell response against tumor cells expressing VEGFR2 (KDR) (PMID: 25867139, PMID: 25502982). | ||
| VEGFR1-1084 | VEGFR1-A24-1084|OTS11101 | VEGFR1-1084 is a FLT1 (VEGFR1) HLA-A*2402 allele-restricted peptide vaccine, which may stimulate a cytotoxic T-cell response against cells expressing FLT1 (VEGFR1), resulting in decreased tumor angiogenesis (PMID: 17020992, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|